Forward Looking Statements

This presentation and our discussion contain forward-looking information and statements, which inherently involve risks and uncertainties that could cause actual results to differ from those projected or implied in the forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements, including those risks and uncertainties discussed in our SEC filings, including our most recent Annual Report on Form 10-K. The forward-looking statements included in this presentation should not be unduly relied upon. These statements speak only as of the date made. Other than as required by applicable law, we do not intend, and do not assume any obligation, to update these forward-looking statements.

This presentation reflects continuing operations.
Our Core Values

Entrepreneurial Spirit
• Be creative, take risks, and show initiative
• Initiate change and innovation
• Take ownership and be accountable

Build Trust
• Be sincere and authentic
• Inform, ask, and listen
• Be supportive and reliable

Make It Fun
• Be collaborative and friendly
• Show appreciation
• Make your work place a better place

People
• People at the center of all we do
• People drive innovation and success
• People make us who we are
Teleflex Today

Our Purpose

• We are a global provider of medical technologies designed to improve the health and quality of people’s lives.

• We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers.

Our Reach

• ~14,000 employees\(^1\) globally

• Global HQ: Wayne, PA, USA

• International HQ: Athlone, Ireland

• Serving healthcare providers worldwide through a combination of our direct sales force and distributors

Our Portfolio

• NYSE listed – TFX

• 2020 revenue of $2.537 billion

• Leading market positions with established global brands

\(^1\)Source: 2020 10-K filing
Making a Difference

Teleflex products are used everyday:

31,000
In 31,000 surgical procedures
in the United States

1,600
To help more than 1,600 patients who
require vascular access intervention
globally

6,000
To care for more than 6,000
patients globally in the Intensive
Care Unit

3,200
By emergency responders to treat
3,200 patients in the field globally

Statistics included in the graphic above were calculated based on 2016 sales data, and management assumptions and estimates
Demographics and Industry Tailwinds

84M
People 65+ years old in U.S. to double by 2050 versus 2012

1B+
People 50+ in Asia by 2025

Lower acuity patients moving to lower cost sites of service

Teleflex Investment Thesis

<table>
<thead>
<tr>
<th>Global Leadership</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Leading positions in growing markets (vascular, interventional access, interventional urology)</td>
</tr>
<tr>
<td>• Established and respected global brands</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Unique Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Global scale to succeed in today’s healthcare marketplace</td>
</tr>
<tr>
<td>• More nimble than larger device companies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Track Record of Execution</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Constant currency revenue growth accelerated to 8.1% in FY19; declined 2.4% in 2020 due to COVID-19</td>
</tr>
<tr>
<td>• 490 basis point adjusted gross margin expansion from 2014 – 2020</td>
</tr>
<tr>
<td>• 520 basis point adjusted operating margin expansion from 2014 – 2020</td>
</tr>
<tr>
<td>• Adjusted earnings per share CAGR of 10.9% from 2014 – 2020</td>
</tr>
</tbody>
</table>

Note: See appendices for reconciliations of non-GAAP financial measures to the most comparable GAAP financial measures.
Leveraging Our Global Infrastructure

Strategies

• Realize margin expansion through ongoing restructuring initiatives

• Leverage recent go-directs to strengthen control of commercial channels in Europe and Asia

• Drive adoption of high margin products in new markets

ORANGE: Americas
BLUE: Europe, Middle East and Africa
GREEN: Asia Pacific
<table>
<thead>
<tr>
<th>Dollars in Millions</th>
<th>FY’20 Revenue</th>
<th>FY’19 Revenue</th>
<th>As-Reported Revenue Growth</th>
<th>Currency Impact</th>
<th>Constant Currency Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Americas</td>
<td>$1,465.0</td>
<td>$1,492.3</td>
<td>(1.8)%</td>
<td>(0.2)%</td>
<td>(1.6)%</td>
</tr>
<tr>
<td>EMEA</td>
<td>$584.9</td>
<td>$588.1</td>
<td>(0.5)%</td>
<td>1.1%</td>
<td>(1.6)%</td>
</tr>
<tr>
<td>Asia</td>
<td>$267.0</td>
<td>$294.3</td>
<td>(9.3)%</td>
<td>0.3%</td>
<td>(9.6)%</td>
</tr>
<tr>
<td>OEM</td>
<td>$220.3</td>
<td>$220.7</td>
<td>(0.2)%</td>
<td>0.4%</td>
<td>(0.6)%</td>
</tr>
<tr>
<td>TOTAL</td>
<td>$2,537.2</td>
<td>$2,595.4</td>
<td>(2.2)%</td>
<td>0.2%</td>
<td>(2.4)%</td>
</tr>
</tbody>
</table>
## Global Product Category Revenue Review

<table>
<thead>
<tr>
<th>Dollars in Millions</th>
<th>FY’20 Revenue</th>
<th>FY’19 Revenue</th>
<th>As-Reported Revenue Growth</th>
<th>Currency Impact</th>
<th>Constant Currency Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vascular Access</td>
<td>$657.7</td>
<td>$600.9</td>
<td>9.5%</td>
<td>0.1%</td>
<td>9.4%</td>
</tr>
<tr>
<td>Interventional</td>
<td>$382.4</td>
<td>$427.6</td>
<td>(10.6)%</td>
<td>0.1%</td>
<td>(10.7)%</td>
</tr>
<tr>
<td>Anesthesia</td>
<td>$302.3</td>
<td>$338.4</td>
<td>(10.7)%</td>
<td>0.2%</td>
<td>(10.9)%</td>
</tr>
<tr>
<td>Surgical</td>
<td>$317.2</td>
<td>$370.1</td>
<td>(14.3)%</td>
<td>0.2%</td>
<td>(14.5)%</td>
</tr>
<tr>
<td>Interventional Urology</td>
<td>$290.0</td>
<td>$290.4</td>
<td>(0.1)%</td>
<td>0.1%</td>
<td>(0.2)%</td>
</tr>
<tr>
<td>OEM</td>
<td>$220.3</td>
<td>$220.7</td>
<td>(0.2)%</td>
<td>0.4%</td>
<td>(0.6)%</td>
</tr>
<tr>
<td>Other(^1)</td>
<td>$367.3</td>
<td>$347.3</td>
<td>5.8%</td>
<td>0.5%</td>
<td>5.3%</td>
</tr>
<tr>
<td>TOTAL</td>
<td>$2,537.2</td>
<td>$2,595.4</td>
<td>(2.2)%</td>
<td>0.2%</td>
<td>(2.4)%</td>
</tr>
</tbody>
</table>

1. Includes revenues generated from sales of the Company’s respiratory and urology products (other than interventional urology products).
Track Record of Revenue Growth, 2011-2020

(in millions)

1. Calculation based on GAAP reported revenue
Note: Bar chart depicts as reported total annual Teleflex revenues
Track Record of Adj. Gross and Operating Margin Expansion

Adjusted Gross Margin

<table>
<thead>
<tr>
<th>Year</th>
<th>Margin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>51.5%</td>
</tr>
<tr>
<td>2015</td>
<td>52.7%</td>
</tr>
<tr>
<td>2016</td>
<td>54.1%</td>
</tr>
<tr>
<td>2017</td>
<td>55.8%</td>
</tr>
<tr>
<td>2018</td>
<td>57.1%</td>
</tr>
<tr>
<td>2019</td>
<td>58.1%</td>
</tr>
<tr>
<td>2020</td>
<td>56.7%</td>
</tr>
</tbody>
</table>

520 bp expansion

Adjusted Operating Margin

<table>
<thead>
<tr>
<th>Year</th>
<th>Margin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>20.0%</td>
</tr>
<tr>
<td>2015</td>
<td>21.5%</td>
</tr>
<tr>
<td>2016</td>
<td>24.1%</td>
</tr>
<tr>
<td>2017</td>
<td>25.1%</td>
</tr>
<tr>
<td>2018</td>
<td>25.7%</td>
</tr>
<tr>
<td>2019</td>
<td>25.8%</td>
</tr>
<tr>
<td>2020</td>
<td>24.9%</td>
</tr>
</tbody>
</table>

490 bp expansion

Note: Figures represent adjusted gross and operating margin. See Appendices for reconciliation of non-GAAP financial measures to the most comparable GAAP financial measures.
Core Strategic Building Blocks

Teleflex is a Differentiated MedTech Asset

Drive Constant Currency Revenue Growth
• Address major healthcare challenges
• Improve outcomes with less invasive, evidence-based procedures
• Accelerate long term revenue growth through scale M&A

Deliver Non-Revenue Dependent Margin Expansion
• Execute restructuring and footprint realignment initiatives
• Take more of our business direct
• Leverage M&A across global infrastructure

Remain a Serial Acquirer
• Acquire high-growth, high-margin businesses with differentiated assets
• Focus on scale and late-stage technologies
• Improve process with each transaction

Align Portfolio with Favorable Demographics
• Focus product suite on procedures that cannot be postponed
• Focus commercial efforts in geographies with improving demographics

Continue to Attract Key Talent
• Focus on culture
• Live our core values
• Keep people at the center of all we do
Teleflex 2021: Three-Year Growth Drivers

2018

- Medium growth company with gross and operating margin expansion
- Investing in key disease states
- Sustained cadence of new product launches
- Driving utilization in growth product categories

2021

- High growth company with gross and operating margin expansion
- Executing on strategic M&A
- Leveraging global infrastructure

Investing in Key Disease States and Markets

- Vascular - Catheter complications
- Interventional – Cardiac procedures
- Surgical - Minimally Invasive Procedures
- Men’s health
- Emergency medicine
Driving Utilization in Growth Product Categories

Current Portfolio

Interventional Urology
- The UroLift® System
- EZ-IQ® Intraosseous Vascular Access System
- OnControl® Powered Bone Access System
- PICCs
- The UroLift® 2 System
- Weck® AutoEndo HOL Large Clip Applier (AE10)
- Wattson

Vascular Access
- Rüsch® Polaris™ Fiber Optic Single-Use Laryngoscope
- Turnpike® Catheters

Airway Management
- Guide Extension

Interventional Cardiology
- Chocolate® PTCA Balloon Catheter
- MANTA® Vascular Closure Device

Select Pipeline
- Freeze Dried Plasma
- The UroLift® System
- Weck® AutoEndo HOL Large Clip Applier (AE10)
- Wattson

^Teleflex Freeze Dried Plasma is not approved for sale or distribution.
Executing Disciplined M&A Strategy

Acquisition Criteria

• Fits existing business units and call points
• Provides superior clinical benefit to existing alternatives
• Provides cost-benefit to the hospital
• Strong IP and patent protection
• Long product life cycles

2011-2020 Cumulative Results

• 74 deals closed\(^1\)
• Transaction value of $4.1 billion

M&A Focus

1. Scale
2. Tuck in
3. Dealer to direct
4. Late-stage technology
5. Reverse integration
## Track Record of Value-Creating Acquisitions

<table>
<thead>
<tr>
<th>M&amp;A Focus</th>
<th>Select Transactions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1 Scale</strong></td>
<td>Z-Medica 2020</td>
</tr>
<tr>
<td><strong>2 Tuck in</strong></td>
<td>QT Vascular 2018</td>
</tr>
<tr>
<td><strong>3 Dealer to direct</strong></td>
<td>VSI Distributors 2017-2018</td>
</tr>
<tr>
<td><strong>4 Late-stage technology</strong></td>
<td>Airway Medix 2017</td>
</tr>
<tr>
<td><strong>5 Reverse integration</strong></td>
<td>IWG HPC 2020</td>
</tr>
<tr>
<td></td>
<td>NeoTract 2017</td>
</tr>
<tr>
<td></td>
<td>Essential Medical 2018</td>
</tr>
<tr>
<td></td>
<td>Human Medics 2015</td>
</tr>
<tr>
<td></td>
<td>Mayo Healthcare 2014</td>
</tr>
<tr>
<td></td>
<td>Truphatek 2015</td>
</tr>
<tr>
<td></td>
<td>Trinris Medical 2015</td>
</tr>
</tbody>
</table>
### Key Investment Highlights

- Diversified, global medical technology company
- Well-positioned to take advantage of favorable industry dynamics
- Leading market positions with established global brands
- Diversified customer and supplier base
- Strong cash flow generation and proven history of deleveraging and margin expansion
- Experienced management team
THANK YOU
Appendix A: Key Products
# NeoTract: A Compelling Growth Asset

<table>
<thead>
<tr>
<th>Significant Market Opportunity</th>
<th>• Initial target market 8.5M U.S. BPH drug or drug drop out patients; $30B+ total addressable market</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exceptional Clinical Data</td>
<td>• 2 randomized controlled trials; 8 single arm studies</td>
</tr>
<tr>
<td></td>
<td>• &gt;28 peer-reviewed publications</td>
</tr>
<tr>
<td></td>
<td>• 5-year follow-up data published</td>
</tr>
<tr>
<td>Established Reimbursement</td>
<td>• CPT1 code January 2015</td>
</tr>
<tr>
<td></td>
<td>• The procedure is covered by Medicare and all national and major commercial plans, when medical criteria are met</td>
</tr>
<tr>
<td>Strong Commercial Infrastructure</td>
<td>• High quality commercial sales force &amp; management team</td>
</tr>
<tr>
<td></td>
<td>• Strong IP position and scalable manufacturing</td>
</tr>
</tbody>
</table>
**UroLift® System: A Large Clinical Need and U.S. Market Opportunity**

- **# of men (millions):**
  - Drugs: 7.0
  - Watchful waiting: 3.2
  - Surgery: 0.3
  - Drug drop out: 1.5

- **8.5 Million**
  - Men on drugs or drug drop out

- **UroLift® System initial target market**
  - $30B+
  - Opportunity

- **~12 Million U.S. men treated for BPH**

---

1. U.S. Market Model 2019-2021 based on IQVIA (IMS Health) data
UroLift® System: EMEA Size of Addressable Market

EMEA represents a significant opportunity for BPH/LUTS treatment

EMEA Addressable Market for UroLift

30+ Mn Actively Managed BPH patients

1. Management estimates. Countries include Austria, Belgium, Denmark, France, Germany, Spain, Sweden, Switzerland, UK, Iran, Iraq, Israel, Jordan, UAE, Egypt, Kenya, Nigeria, South Africa, Uganda, and Zimbabwe, among others.
Asia Pacific represents a significant opportunity for BPH/LUTS treatment

1. Management estimates. Countries include Australia, China, India, Indonesia, Japan, among others.
UroLift® System: A Straightforward Procedure

Apply Lidocaine jelly/oral sedative¹
Gently push tissue aside
Relieve obstruction

Insert delivery system
Deploy customized implants
Typically same day discharge

¹ This does not account for the physician’s preferred anesthesia protocol.
UroLift® 2 System

One implant per cartridge

- UroLift Implant design remains the same
- With the UroLift® 2 System, multiple cartridges per handle enable greater ease of use and reduce medical waste
UroLift® ATC™ System

- UroLift® Advanced Tissue Control (ATC™) is an optimized delivery device that offers enhanced tissue control in cases with challenging anatomy such as obstructive median lobe (OML) or large lateral lobes.

- Wings at the tip allow the urologist to better grab and mobilize tissue into place prior to implant deployment.

- ~15% of BPH patients present with OML.¹

¹ Doo, Urology 2009; 73: 232-236. Obstructive Middle Lobe was defined as high intravesical prostatic protrusion (IPP: grade 3, >10mm into bladder) and calculated as all patients with prostate contour Type 2 (2.5%) + 73.3% of patients with contour Type 3 (19.1%) = 16.5%. 
UroLift: Reducing Tradeoffs Between Effectiveness and Risk Compared to Drugs

Time to First Evidence of Statistically Significant Relief (Weeks)\textsuperscript{1,2,3,4,5}

<table>
<thead>
<tr>
<th>5ARI</th>
<th>AB</th>
<th>UROLIFT</th>
</tr>
</thead>
<tbody>
<tr>
<td>12-24</td>
<td>1-3</td>
<td>2</td>
</tr>
</tbody>
</table>

Symptom Improvement at 10-16 Months\textsuperscript{5,6,7}

<table>
<thead>
<tr>
<th>Mean AUASI Reduction</th>
<th>5ARI</th>
<th>AB</th>
<th>UROLIFT</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.4</td>
<td>5.6-7.5</td>
<td>10.8</td>
<td></td>
</tr>
</tbody>
</table>

Incidence of Sexual Dysfunction

<table>
<thead>
<tr>
<th>Ejaculatory Dysfunction</th>
<th>5ARI</th>
<th>AB</th>
<th>UROLIFT\textsuperscript{5,7}</th>
</tr>
</thead>
<tbody>
<tr>
<td>4%</td>
<td>0%-10%</td>
<td>0%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Erectile Dysfunction</th>
<th>5ARI</th>
<th>AB</th>
<th>UROLIFT\textsuperscript{5,7}</th>
</tr>
</thead>
<tbody>
<tr>
<td>8%</td>
<td>3%-5%</td>
<td>0%</td>
<td></td>
</tr>
</tbody>
</table>

\textsuperscript{5} Sexual Dysfunction defined as new, onset sustained erectile or ejaculatory dysfunction.

DRUGS: 5ARI = 5 alpha reductase inhibitors  \ AB = alpha blockers

Symptoms measured by AUASI (American Urological Association Symptom Index)

\textsuperscript{1} Roehrborn, Rev Urol 2009; 11(suppl 1): S1-S8; \textsuperscript{2} Rossi, Drug Des, Dev and Therap 2010; 4: 291-297; \textsuperscript{3} Pearson, Am Fam Phys 2014; 90 (11): 769-774; \textsuperscript{4} Cindolo, Eur Urol 2015 Sep; 68(3): 418-25; \textsuperscript{5} Roehrborn, J Urol 2013; 190: 2161-2167; \textsuperscript{6} Sonksen, Eur Urol 2015; 68: 643-652; \textsuperscript{7} AUA Guidelines 2003, 2010, 2014, which address a range of outcomes across alfuzosin, doxazosin, tamsulosin, and terazosin for ABs and only finasteride for 5ARIs
Anesthesia and Emergency Medicine

Top Market Trends

- >137 million visits to the emergency room in the U.S. annually.¹
- There are >500,000 adult occurrences of cardiac arrest yearly in the US with an estimated 10% survival rate.²
- Sepsis kills a patient in the U.S. every 2.3 Minutes.³ As many as 80% of sepsis deaths could be prevented with rapid diagnosis and treatment.⁴
- The EZ-IQ® system enables rapid intravenous access in urgent emergent access situations that may include trauma or septic shock.

Growth Strategy

- Go deep in high potential accounts
- Sustained leadership in professional, clinical and product training
- Methodical training on protocol for optimal outcomes
- Expand IP position in mechanical intraosseous access segment

Anesthesia and Emergency Medicine

Top Market Trends

- >137 million visits to the emergency room in the U.S. annually\(^1\)
- Minimal plasma availability in challenging environments (prehospital, remote/rural, battlefield settings), despite demand and opportunity to save many lives
- Traumatic injuries with hemorrhage require plasma transfusion to help stop life-threatening bleeding
- FDA and DoD launched joint program to expedite medical products intended to save lives of US military; including Freeze Dried Plasma

Growth Strategy

- Partner with DOD through accelerated EUA/BLA regulatory pathway; conduct confirmatory efficacy study post licensure
- Establish battlefield (medic) and prehospital/remote settings (EMS paramedic)
- Expand to Trauma centers in hospital

Freeze Dried Plasma

\(^1\) CDC: National Hospital Ambulatory Medical Care Survey: 2015 Emergency Department Summary Tables

Freeze Dried Plasma is not approved for sale or distribution
Freeze Dried Plasma Market

Market Size Estimate

- Government
  ~$20M - $25M

- Civilian*
  ~$70M - $75M

Total market size
~$100M

Source: Management estimates
*Does not include civilian trauma hospitals. Teleflex Freeze Dried Plasma is not approved for sale or distribution
Coronary and Structural Heart Disease

Top Market Trends

• Coronary artery disease is the most common type of heart disease in the US – cause of more than 370,000 deaths annually
• Over 1 million percutaneous coronary interventions (PCI) are performed in the US every year
• More than five million Americans are diagnosed with heart valve disease each year
• Approximately 8.5 million Americans suffer from peripheral arterial disease (PAD)

Growth Strategy

• Expand new product pipeline
• Build brand awareness
• Expand professional education programs
• Deliver growth through M&A

1. CDC: https://www.cdc.gov/heartdisease/facts.htm
4. CDC: https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_pad.htm

Arrow® OnControl® Powered Bone Access System

~$160M
Total Potential Addressable U.S. Market1

• Up to 55% faster procedure time to improve efficiency versus manual biopsy needles1

• Fewer second-attempt procedures required versus manual biopsy needles1,2

• Consistently larger, high-quality core specimens versus manual biopsy needles2,3,4,5

• Increased user control and reduced physical requirements to obtain specimens6,7

• Demonstrated significantly less patient pain after the procedure than with use of manual biopsy needles2,4

Results may vary from patient to patient. Rx only.

The Arrow® OnControl® Powered Bone Access System should only be used by clinicians familiar with the complications, limitations, indications, and contraindications of the indicated procedures. See Instructions For Use provided with the OnControl.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.

**Arrow® AC3 Optimus® Intra-Aortic Balloon Pump**

**Simply outstanding performance, support, and efficiency in an IABP**

For patients requiring mechanical cardiac support, the performance of the IABP can mean all the difference. With the onset of an elevated heart rate or arrhythmia, the patient’s survival can suddenly depend on the ability of the IABP to keep pace with the situation. The AC3 Optimus® Intra-Aortic Balloon Pump provides intra-beat inflation timing accuracy across a wide range of patient conditions — including those with severe arrhythmias.¹,²

---

¹. Donelli A, Jansen JRC, Hoeksel B, et. al. Performance of a real-time dicrotic notch detection and prediction algorithm in arrhythmic human aortic pressure signals. J Clin Moni. 2002;17(3-4):181-185. Study sponsored by Teleflex. Dr. Schreuder was formerly a paid consultant of the study sponsor. Co-authors J. Bovelander and R. Hanania are current or former employees of the study sponsor.

Manta® Vascular Closure Device

A new era of simplicity and confidence in large bore closure

The MANTA® Device is the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure.¹ Available in 14 Fr. and 18 Fr., a single MANTA Device effectively closes femoral arterial access sites following the use of large bore sheaths ranging from 12 Fr. to 25 Fr. O.D. ²

Simple deployment
• Addresses the challenges of femoral arterial access site closure with a single easy-to-use device.²

Rapid hemostasis
• Reduces time to hemostasis without pre-closure, utilizing the coagulation-inducing properties of collagen for rapid hemostasis to promote vessel healing.²,³,⁴,⁵

Reliable closure
• Delivers reproducible results and helps inspire confidence in achieving successful closure.²

¹ Data on file at Teleflex. ² Data on file at Teleflex. The SAFE MANTA IDE Clinical Trial. ²a Major Complications defined as composite of: i) vascular injury requiring surgical repair/stent-graft; ii) bleeding requiring transfusion; iii) lower extremity ischemia requiring surgery/spinal decompression; iv) infection requiring IV antibiotics and/or extended hospitalization. ²b A single MANTA™ Device was deployed in 99.6% of subjects in the IDE trial. ²c The MANTA™ Device demonstrated a time to hemostasis (TTH) of 24 seconds median time (65 seconds mean time) from deployment to hemostasis, which is lower than published rates for Perclose ProGlide® where Perclose ProGlide® demonstrated a TTH of 9.8 +/- 17 minutes (588 +/- 1,020 seconds). ³ 97.7% Technical Success, defined as percutaneous vascular closure obtained with the MANTA™ Device without the use of unplanned endovascular or surgical intervention. ³ Nelson PR, et al. A multicenter, randomized, controlled trial of totally percutaneous access versus open femoral exposure for endovascular aortic aneurysm repair (the PEVAR trial). J Vasc Surg. 2014 May;59(5):1081-1193. ⁴ Farndale RW, et al. The role of collagen in thrombosis and hemostasis. J Thromb Haemost. 2004 Apr;2(4):564-573. ⁵ Nuyttens BP, et al. Platelet adhesion to collagen. Thromb Res. 2011;127(3): S26-S29.
**Guideliner® V3 Catheter**

**Guide extension catheter with half-pipe technology**

The GuideLiner® Catheter revolutionized the concept of guide extension, creating new possibilities in interventional cardiology. Now in its third generation, the GuideLiner® V3 Catheter continues to build on a history of innovation and performance—one that's been demonstrated with more than half a million catheters in cath labs around the world.¹

**Half-pipe technology**
The half-pipe channel is designed to minimize device/collar interaction by directing and aligning devices through the collar transition, facilitating smooth device entry and seamless delivery.

¹ Data on file.
Turnpike® Catheters

**Turnpike® Spiral Catheter**
Distal nylon coil provides rotational assistance for enhanced trackability

**Turnpike® Gold Catheter**
Gold-plated, threaded metallic tip for enhanced advancement

**Turnpike® LP Catheter**
Low-profile version with greater tip and distal shaft flexibility for advancement through extreme tortuosity
**TrapLiner® Catheter**

**Guide Extension Plus Wire Trapping**

- Balloon inflates to maintain guidewire position
- Rapid exchange guide extension for backup support and deep-seating
- Gold radiopaque marker identifies trapping balloon location

Balloon inflates via a hypotube push rod to trap the guidewire against the interior wall of the guide catheter

Guideliner® Catheter design but with shortened rapid exchange guide extension segment and hydrophilic coating
A Less Invasive Surgical Approach

Top Market Trends

- 3.5 million laparoscopic procedures performed in the US Annually\(^1\)
- Patient and clinician demand for decreased trauma and enhanced safety
- Patient satisfaction influence on reimbursement

Growth Strategy

- Broad awareness through market development activities generate demand for targeted elective procedures
- Deepen surgical congress society relationships
- Build clinical evidence with key teaching institutions
- Continued investment in refining and broadening product portfolio

1. Idata research: United States Market Report Suite for Laparoscopic Devices, 2017
Weck® Hem-o-lok® Polymer Ligation Systems

Product Description

Weck® Hem-o-lok® polymer ligation clips are designed for cool ligation, lasting security and fast, efficient delivery – secure from the cartridge to the applier and on the vessel. The Weck® Hem-o-lok® polymer ligation system unique design offers:

- A flexible hinge that keeps the clip firmly seated in the applier jaws
- Tactile feedback that confirms jaw seating and secure vessel placement
- Distal locking clip to signal closure
Catheter Complications: Antimicrobial Technology

Top Market Trends

• Increasing awareness of vascular-related complications with PICCs and midlines
• Pressures on healthcare funding linked to patient outcomes
• Increasing awareness of infection and thrombosis driving penalties and therapy costs

Growth Strategy

• Portfolio enhancement around reducing vascular-related complications that equally benefit patients and clinicians
• Data driven, health economic selling and consultative approaches
• Leverage tip placement navigation technology in PICCs and CVCs
• Drive standardization through our coating and kitting strategies
• Investment and launch of several clinical education and professional education programs
The latest addition to the Arrow® Brand represents an evolution in progressive design, featuring clinician-inspired enhancements. We observed thousands of hours of procedures to create an intuitive configuration that allows for efficient procedural workflow and compliance with clinical best practices.

Key features include an intuitive layout of components, smart labeling, a kink-resistant nitinol wire, transducer cover, option for innovative dressing technologies, and Arrow® GlideWheel™ Advancer.
1. As compared to uncoated PICCs, intravascular ovine model inoculated with Staph aureus. No correlation between these testing methods and clinical outcome has currently been ascertained. 2. In vitro data on file 2010. No correlation between these testing methods and clinical outcome has currently been ascertained.

Arrowg+ard Blue Advance® Catheters are contraindicated in the following areas:
- Patients with known hypersensitivity to chlorhexidine
- In presence of device related infections
- In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway.

Arrowg+ard Blue Advance® PICCs are the world’s first PICCs in the intravascular catheter marketplace with both broad-spectrum antimicrobial and antithrombogenic protection. Extra- and intraluminal protection helps reduce the colonization of some pathogens responsible for causing central line-associated bloodstream infections (CLABSIs).\(^1,2\) Chlorhexidine helps to reduce thrombus accumulation on the catheter surfaces.\(^1\) The Arrowg+ard Blue Advance® PICC is available in a complete portfolio of single-, double- and triple-lumen formats and related kits.

Product Description

Pressure-injectable Arrowg+ard Blue Advance® PICCs are the world’s first PICCs in the intravascular catheter marketplace with both broad-spectrum antimicrobial and antithrombogenic protection. Extra- and intraluminal protection helps reduce the colonization of some pathogens responsible for causing central line-associated bloodstream infections (CLABSIs).\(^1,2\) Chlorhexidine helps to reduce thrombus accumulation on the catheter surfaces.\(^1\) The Arrowg+ard Blue Advance® PICC is available in a complete portfolio of single-, double- and triple-lumen formats and related kits.

1. As compared to uncoated PICCs, intravascular ovine model inoculated with Staph aureus. No correlation between these testing methods and clinical outcome has currently been ascertained. 2. In vitro data on file 2010. No correlation between these testing methods and clinical outcome has currently been ascertained. Arrowg+ard Blue Advance® Catheters are contraindicated in the following areas:
- Patients with known hypersensitivity to chlorhexidine
- In presence of device related infections
- In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway.
Appendix B:
GAAP to Non-GAAP Reconciliations
Note on Non-GAAP Financial Measures

The presentation to which these appendices are attached, and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measure:

- **Constant currency revenue growth.** This measure excludes the impact of translating the results of international subsidiaries at different currency exchange rates from period to period.

- **Adjusted gross profit and margin.** These measures exclude, depending on the period presented, the impact of (i) restructuring, restructuring related and impairment items, (ii) acquisition, integration and divestiture related items and (iii) other items identified in note (C) to the reconciliation tables appearing in Appendix B.

- **Adjusted operating profit and margin.** These measures exclude, depending on the period presented, (i) the impact of restructuring, restructuring related and impairment items; (ii) acquisitions, integration and divestiture related items; (iii) other items identified in note (C) to the reconciliation tables appearing in Appendix C.

- **Adjusted diluted earnings per share.** This measure excludes, depending on the period presented, the impact of (i) restructuring, restructuring related and impairment items; (ii) acquisition, integration and divestiture related items; (iii) other items identified in note (C) to each of the reconciliation tables appearing in Appendices D and E; (iv) amortization of the debt discount on the Company’s previously outstanding convertible notes; (v) intangible amortization expense; (vi) loss on extinguishment of debt; and (vii) tax adjustments identified in note (G) to the reconciliation tables appearing in Appendices D and E. In addition, the calculation of diluted shares within adjusted earnings per share for the 2017 periods gives effect to the anti-dilutive impact of the Company’s previously outstanding convertible note hedge agreements, which reduced the potential economic dilution that otherwise would have occurred upon conversion of the Company’s senior subordinated convertible notes (under GAAP, the anti-dilutive impact of the convertible note hedge agreements is not reflected in diluted shares).
Non-GAAP Adjustments

The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non-GAAP financial measures that appear in the presentation to which these appendices are attached:

**Restructuring, restructuring related and impairment items.** Restructuring programs involve discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies and integrate acquired businesses. Depending on the specific restructuring program involved, our restructuring charges may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement and other exit costs associated with the restructuring program. Restructuring related charges are directly related to our restructuring programs and consist of facility consolidation costs, including accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of the restructuring program. Impairment charges occur if, as a result of periodic impairment testing or due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity but could have a material adverse effect on our reported financial results.

**Acquisition, integration and divestiture related items.** Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; legal entity restructuring expense; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; and bridge loan facility and backstop financing fees in connection with loan facilities that ultimately were not utilized. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of the divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.

**Other items.** These are discrete items that occur sporadically and can affect period-to-period comparisons.

**Amortization of debt discount on convertible notes.** When we sold $400 million principal amount of our 3.875% convertible notes (the "convertible notes") in 2010, we allocated the proceeds between the liability and equity components of the debt, in accordance with GAAP. As a result, the $83.7 million difference between the proceeds of the sale of the convertible notes and the liability component of the debt constituted a debt discount that was to be amortized to interest expense over the approximately seven-year term of the convertible notes, which significantly increased the amount we recorded as interest expense attributable to the convertible notes. The amount of the amortization of the debt discount was reduced as a result of our repurchases of convertible notes in 2016 and 2017 and redemptions of the convertible notes by holders of the notes, although we continued to amortize the remaining portion of the debt discount to interest expense until August 2017, when all remaining convertible notes were either converted or matured.

**Intangible amortization expense.** Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.

**Loss on extinguishment of debt.** In connection with debt refinancings, debt repayments, repurchases of convertible notes and redemptions of convertible notes, outstanding indebtedness is extinguished. These events, which have occurred from time to time on an irregular basis, have resulted in losses reflecting, among other things, unamortized debt issuance costs, as well as debt prepayment fees and premiums (including conversion premiums resulting from conversion of convertible securities).

**Tax adjustments.** These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law changes affecting our deferred tax liability.

**Adjusted diluted shares.** Adjusted diluted shares are calculated by giving effect to the anti-dilutive impact of the Company's convertible note hedge agreements, which reduced the potential economic dilution that otherwise would have occurred upon conversion of the Company's convertible notes. Under GAAP, the anti-dilutive impact of the convertible note hedge agreements is not reflected in the weighted average number of diluted shares.
Appendix A – Reconciliation of Adjusted Gross Profit and Margin
Dollars in Thousands

<table>
<thead>
<tr>
<th></th>
<th>Twelve Months Ended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross profit as-reported</td>
<td>$942,428$</td>
</tr>
<tr>
<td>Gross margin as-reported</td>
<td>51.2%</td>
</tr>
<tr>
<td>Restructuring, restructuring related and impairment items (A)</td>
<td>4,886</td>
</tr>
<tr>
<td>Acquisition, integration and divestiture related items (B)</td>
<td>-</td>
</tr>
<tr>
<td>Other items (C)</td>
<td>-</td>
</tr>
<tr>
<td>Intangible Amortization (D)</td>
<td>-</td>
</tr>
<tr>
<td>Adjusted gross profit</td>
<td>$947,314$</td>
</tr>
<tr>
<td>Adjusted gross margin</td>
<td>51.5%</td>
</tr>
<tr>
<td>Revenue as-reported</td>
<td>$1,839,832$</td>
</tr>
</tbody>
</table>
Appendix B – Reconciliation of Adjusted Operating Profit and Margin
Dollars in Thousands

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>收入</td>
<td>$284,862</td>
<td>$315,891</td>
<td>$319,453</td>
<td>$372,279</td>
<td>$321,704</td>
<td>$427,254</td>
<td>$423,068</td>
</tr>
<tr>
<td>收入占总收入的百分比</td>
<td>15.5%</td>
<td>17.5%</td>
<td>17.1%</td>
<td>17.3%</td>
<td>13.1%</td>
<td>16.5%</td>
<td>16.7%</td>
</tr>
<tr>
<td>重组、重组相关及减值项目 (A)</td>
<td>28,749</td>
<td>17,314</td>
<td>74,559</td>
<td>29,371</td>
<td>93,957</td>
<td>38,490</td>
<td>65,226</td>
</tr>
<tr>
<td>收购、整合及处置相关项目 (B)</td>
<td>(7,549)</td>
<td>(3,498)</td>
<td>(7,399)</td>
<td>38,802</td>
<td>60,321</td>
<td>49,299</td>
<td>(28,805)</td>
</tr>
<tr>
<td>其他项目 (C)</td>
<td>600</td>
<td>(3,040)</td>
<td>572</td>
<td>(551)</td>
<td>2,907</td>
<td>1,814</td>
<td>1,078</td>
</tr>
<tr>
<td>无形资产摊销 (D)</td>
<td>60,926</td>
<td>62,380</td>
<td>63,491</td>
<td>98,766</td>
<td>149,486</td>
<td>149,974</td>
<td>158,685</td>
</tr>
<tr>
<td>MDR成本 (E)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,194</td>
<td>11,267</td>
<td>-</td>
</tr>
<tr>
<td>调整后的收入</td>
<td>$367,588</td>
<td>$389,047</td>
<td>$450,676</td>
<td>$538,667</td>
<td>$628,375</td>
<td>$670,025</td>
<td>$632,519</td>
</tr>
<tr>
<td>调整后的收入占总收入的百分比</td>
<td>20.0%</td>
<td>21.5%</td>
<td>24.1%</td>
<td>25.1%</td>
<td>25.7%</td>
<td>25.8%</td>
<td>24.9%</td>
</tr>
<tr>
<td>总收入</td>
<td>$1,839,832</td>
<td>$1,809,690</td>
<td>$1,868,027</td>
<td>$2,146,303</td>
<td>$2,448,383</td>
<td>$2,595,362</td>
<td>$2,537,156</td>
</tr>
</tbody>
</table>
## Appendix C – Reconciliation of Adjusted Earnings per Share

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GAAP diluted earnings per share available to common shareholders</strong></td>
<td>$4.10</td>
<td>$4.91</td>
<td>$4.98</td>
<td>$3.33</td>
<td>$4.20</td>
<td>$9.81</td>
<td>$7.10</td>
<td>9.6%</td>
</tr>
<tr>
<td><strong>GAAP year-over-year growth</strong></td>
<td>19.8%</td>
<td>1.4%</td>
<td>-33.1%</td>
<td>26.1%</td>
<td>133.6%</td>
<td>-27.6%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restructuring, restructuring related and impairment items (A)</strong></td>
<td>0.45</td>
<td>0.23</td>
<td>1.03</td>
<td>0.44</td>
<td>$1.76</td>
<td>0.71</td>
<td>1.32</td>
<td></td>
</tr>
<tr>
<td><strong>Acquisition, integration and divestiture related items (B)</strong></td>
<td>(0.17)</td>
<td>(0.09)</td>
<td>(0.11)</td>
<td>0.79</td>
<td>$1.27</td>
<td>1.11</td>
<td>(0.59)</td>
<td></td>
</tr>
<tr>
<td><strong>Other items (C)</strong></td>
<td>0.01</td>
<td>(0.04)</td>
<td>0.01</td>
<td>0.01</td>
<td>$0.06</td>
<td>0.17</td>
<td>0.02</td>
<td></td>
</tr>
<tr>
<td><strong>MDR costs (D)</strong></td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td><strong>Amortization of debt discount on convertible notes</strong></td>
<td>0.17</td>
<td>0.17</td>
<td>0.10</td>
<td>0.01</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td><strong>Intangible amortization expense</strong></td>
<td>0.94</td>
<td>0.95</td>
<td>0.99</td>
<td>1.52</td>
<td>$2.63</td>
<td>2.59</td>
<td>2.84</td>
<td></td>
</tr>
<tr>
<td><strong>Loss on extinguishment of debt</strong></td>
<td>—</td>
<td>0.14</td>
<td>0.26</td>
<td>0.08</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td><strong>Tax adjustments</strong></td>
<td>(0.09)</td>
<td>(0.39)</td>
<td>(0.23)</td>
<td>2.17</td>
<td>($0.01)</td>
<td>(3.31)</td>
<td>(0.25)</td>
<td></td>
</tr>
<tr>
<td><strong>Shares due to Teleflex under note hedge</strong></td>
<td>0.33</td>
<td>0.44</td>
<td>0.31</td>
<td>0.05</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted diluted earnings per share available to common shareholders</strong></td>
<td>$5.74</td>
<td>$6.33</td>
<td>$7.34</td>
<td>$8.40</td>
<td>$9.90</td>
<td>$11.15</td>
<td>$10.67</td>
<td>10.9%</td>
</tr>
<tr>
<td><strong>Adjusted year-over-year growth</strong></td>
<td>10.3%</td>
<td>16.0%</td>
<td>14.4%</td>
<td>17.9%</td>
<td>12.6%</td>
<td>-4.3%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Restructuring, restructuring related and impairment items – In 2014 and 2015, the majority of these charges were related to facility consolidations. In 2016, these charges include: (i) charges related to facility consolidations, (ii) a pre-tax, non-cash $41.0 million impairment charge and a $14.9 million reduction in related deferred tax liabilities in connection with discontinuation of an in-process research and development project; (iii) $2.4 million in pre-tax, non-cash impairment charges related to two properties, one of which was classified as an asset held for sale and (iv) a $0.7 million reduction in related deferred tax liabilities. For the twelve months ended December 31, 2017 and December 31, 2018, pre-tax restructuring related charges were $14.6 million and $14.7 million, respectively. For the twelve months ended December 31, 2017 and December 31, 2018, pre-tax impairment charges were $0.0 million and $19.1 million, respectively. For the twelve months ended December 31, 2019 pre-tax restructuring related charges were $15.2 million, pre-tax restructuring related charges were $16.3 million, and pre-tax impairment charges were $7.0 million. For the twelve months ended December 31, 2020, pre-tax restructuring charges were $17.1 million, pre-tax restructuring related charges were $26.7 million, and pre-tax impairment charges were $21.4 million.

Acquisition, integration and divestiture related items - In 2014 and 2015, the majority of these charges were related to contingent consideration liabilities, somewhat offset by acquisition costs. In 2016, the majority of these charges were related to reversals related to contingent consideration liabilities, including $8.3 million related to the discontinuation of an in-process research and development project, and the gain on a sale of assets, somewhat offset by acquisition costs. For the twelve months ended December 31, 2017, these charges were primarily related to our acquisitions of Vascular Solutions and NeoTract, as well as contingent consideration liabilities. For the twelve months ended December 31, 2018, these charges were primarily related to contingent consideration liabilities and our acquisition of NeoTract. For the twelve months ended December 31, 2019, these charges primarily related to contingent consideration liabilities and our acquisition of Essential Medical, Inc., partially offset by the gain on sale of a business and two assets. For the year ended December 31, 2020, these items primarily related to the reversal of contingent consideration liabilities, partially offset by charges primarily related to our acquisitions of IWG High Performance Conductors, Inc. and Z-Medica, LLC. and the reversal of previously recognized income related to a distributor conversion in Japan.

Other items - In 2015, the majority of these charges were related to the medical device excise tax and a litigation verdict against the Company with respect to a non-operating joint venture. In 2016, the majority of these charges were related to relabeling costs and costs associated with a facility that was exited. For the twelve months ended December 31, 2017, other items included both gains and losses associated with litigation settlements, the reversal of previously recognized income due to distributor acquisitions related to Vascular Solutions, the reversal of previously recognized income due to our distributor to direct sales conversion in China, and relabeling costs. For the twelve months ended December 31, 2018, other items included the reversal of previously recognized income due to distributor acquisitions related to Vascular Solutions, losses associated with settlement of litigation relating to an intellectual property matter, expenses associated with a franchise tax audit, and relabeling costs. Other items for the twelve months ended December 31, 2019, pre-tax restructuring related charges were $16.3 million, and pre-tax impairment charges were $7.0 million. For the twelve months ended December 31, 2020, other items included debt modification and extinguishment expenses, expenses associated with a franchise tax audit, and product relabeling costs, partially offset by a credit associated with an insurance settlement. For the year ended December 31, 2020, other items included expenses associated with a franchise tax audit and prior year tax matters.

Intangible Amortization - For the twelve months ended December 31, 2018 and December 31, 2019, we reclassified $81.6 million and $82.6 million respectively, from selling, general and administrative expenses to cost of goods sold. For the year ended December 31, 2020 intangible asset amortization expense of $84.4 million is included in cost of goods sold.

MDR - For the twelve months ended December 31, 2020 and December 31, 2019, these costs were associated with our efforts to comply with the European Medical Device Regulation. The costs associated with the European Medical Device Regulation initiative include $0.3 million that were a component of the "Other items" line item in the reconciliation table for the three months ended March 31, 2019 included in our first quarter 2019 earnings release.